Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $4 to $6, according to analysts polled by Capital IQ. (MT...
Leap Therapeutics (LPTX) said Monday that it has teamed up with Leica Biosystems to develop a companion diagnostic to detect Dickkopf-related protein 1....
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Health care stocks were edging higher premarket Wednesday. The iShares Biotechnology ETF (IBB) was up by 0.64% while the Health Care SPDR (XLV) was 0.02%...
| Address | 47 Thorndike Street Cambridge, Massachusetts 02141 |
| Phone | +1.617.714.0360 |
| Number of Employees | 25 |
| Recent SEC Filing | 06/16/2022 8-K |
| President, CEO, CFO, Secretary & Treasurer | Doug E. Onsi |
| Chief Operating Officer | Augustine J. Lawlor |
| Chief Medical Officer | Cynthia Sirard |
| Head-Research | Michael Haas |
| Price Open | $1.21 |
| Previous Close | $1.21 |
| 52 Week Range | $0.92 - 4.17 |
| Market Capitalization | $108.6 M |
| Shares Outstanding | 88.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/12/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.48 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -3,718.13% |
| Return on Equity | -47.38% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
